Novartis To Present New Data On Multiple Sclerosis Treatment

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Novartis To Present New Data On Multiple Sclerosis Treatment

Postby MSUK » Wed Mar 13, 2013 1:46 am

Novartis AG said it will present new data on Multiple Sclerosis or MS treatment at the 65th annual meeting of the American Academy of Neurology or AAN.

It will highlight growing clinical trial and real-world experience with Gilenya (fingolimod), the first once-daily oral therapy approved to treat people with relapsing MS or RMS. Updates on studies of Gilenya in people with primary-progressive MS or PPMS and the investigational agent BAF312 (siponimod) in people with secondary-progressive MS or SPMS will also be communicated, the company said... Read More - http://www.ms-uk.org/index.cfm/gilenya
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2092
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Gilenya

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users